Who is sponsoring NCT06161220?

NCT06161220 is sponsored by Impax Laboratories, LLC.

What drugs are being tested in NCT06161220?

Interventions in NCT06161220: Carbidopa capsule, Moxifloxacin Tablets, USP, Placebo.

What condition does NCT06161220 study?

NCT06161220 studies Cardiac Repolarization in Healthy Subjects.

Is NCT06161220 still recruiting?

NCT06161220 is currently completed. Last updated 5 March 2024.

Last reviewed 2024-03-05 · How we verify

NCT06161220

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

Completed Phase 1 Last updated 5 March 2024

What this trial tests

Phase 1 trial testing Carbidopa capsule in Cardiac Repolarization in Healthy Subjects in 35 participants. Completed in 5 December 2023.

Timeline

30 October 2023

Primary endpoint
3 December 2023

5 December 2023

Quick facts

Lead sponsor	Impax Laboratories, LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	35
Start date	30 October 2023
Primary completion	3 December 2023
Estimated completion	5 December 2023
Sites	1 location across United States

Drugs / interventions tested

Carbidopa capsule — full drug profile →
Moxifloxacin Tablets, USP — full drug profile →
Placebo

Conditions studied

Cardiac Repolarization in Healthy Subjects — all drugs for Cardiac Repolarization in Healthy Subjects →

Sponsor

Impax Laboratories, LLC — full company profile →

Who can join

Adults 18 to 55, any sex, with Cardiac Repolarization in Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Impax Laboratories, LLC trials

Trials by the same sponsor.

NCT03877510 — Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants W · Phase 3 · completed
NCT03670953 — A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations · Phase 3 · completed
NCT03275922 — Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE · Phase 3 · completed
NCT03007888 — A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06161220 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Impax Laboratories, LLC
Last refreshed: 5 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06161220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing